{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.0","upperLimit":"266.0","value":"155.0"},{"groupId":"OG001","lowerLimit":"23.0","upperLimit":"55.0","value":"42.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"description":"Time to first RBC transfusion is defined as time from Week 1 to first RBC transfusion on treatment. Participants who maintain RBC-TI through the end of the Treatment Period or time of analysis will be censored at EOT visit date, subsequent MDS therapy start date, study discontinuation date, analysis cutoff date or death, whichever occurs first. Median is from un-stratified Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEDIAN","populationDescription":"ITT Population - all randomized participants regardless of whether or not the participant received treatment.","reportingStatus":"POSTED","timeFrame":"Week 1 through End of Treatment (Up to approximately an average of 66 weeks and a maximum of 202 weeks)","title":"Time to First Red Blood Cell (RBC) Transfusion","type":"SECONDARY","unitOfMeasure":"Days"}